Safety Follow-up Study of Cellgram-ED in Post-Radical Prostatectomy Erectile Dysfunction
A Safety Follow-up Study of a Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Cellgram-ED (Autologous Bone Marrow-Derived Mesenchymal Stem Cells) in Patients With Post-Radical Prostatectomy Erectile Dysfunction
Pharmicell Co., Ltd.
32 participants
Dec 26, 2024
OBSERVATIONAL
Conditions
Summary
This phase II clinical trial with safety follow-up is designed to evaluate the efficacy and safety of Cellgram-ED (autologous bone marrow-derived mesenchymal stem cells) administered via intracavernous injection in patients with erectile dysfunction after radical prostatectomy.
Eligibility
Inclusion Criteria2
- Participants who previously participated in the parent clinical trial and received the cell therapy (Cellgram-ED).
- Participants who have provided written informed consent to participate in this safety follow-up study.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07431008